REG - Sareum Holdings PLC - Director/PDMR Shareholding

Sareum HoldingsAnnouncement

29/12/2022 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221229:nRSc2434La&default-theme=true

RNS Number : 2434L  Sareum Holdings PLC  29 December 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Director's Dealing

Cambridge, UK, 29 December - Sareum Holdings plc (AIM: SAR), a biotechnology
company developing next generation kinase inhibitors for autoimmune disease
and cancer, announces that Dr Stephen Parker, Non-Executive Chairman,
purchased 19,972 ordinary shares of 0.0125 pence each in the Company
("Ordinary Shares") at an average price of 77.6 pence per share on 28 December
2022.  Shares are held in either Dr. Parker's SIPP or an ISA account.

The notification below, which has been made in accordance with the
requirements of the Market Abuse Regulation, provides further details.

Following the transaction, Dr Parker has a holding in Sareum of 103,660
Ordinary Shares, from a previous holding of 83,688 Ordinary Shares.

PDMR Notification Form:

 1           Details of the person discharging managerial responsibilities/person closely
             associated

 a)          Name                            Stephen Parker
 2           Reason for the notification
 a)          Position/status                 Non-Executive Chairman
 b)          Initial notification/amendment  Initial notification
 3           Details of the issuer, emission allowance market participant, auction
             platform, auctioneer or auction monitor
 a)          Name                            Sareum Holdings plc
 b)          LEI                             213800PKERN2DY8FFM72
 4           Details of the transaction(s): section to be repeated for (i) each type of
             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
             place where transactions have been conducted
 a)          Description of the financial instrument, type of instrument     Ordinary shares of 0.0125 pence each in the share capital of Sareum Holdings
                                                                             plc

             Identification code                                             GB00B02RFS12

 b)          Nature of the transaction                                       Purchase of shares
 c)          Price(s) and volume(s)
                                                                                                   Price(s)              Volume(s)
             Hargreaves Lansdown SIPP                                                              £0.78                 12,820
             Barclays Investment ISA                                                               £0.769                7,152

 d)          Aggregated information

             -      Aggregated volume                                        19,972 ordinary shares

             -      Weighted Average Price                                   77.61 pence per share

 e)          Date of the transaction                                         28 December 2022
 f)          Place of the transaction                                        London Stock Exchange (AIM)

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014, which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                         020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a biotechnology company developing next
generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC 1801, simultaneously inhibits TYK2 and JAK1. SDC1801
is a potential treatment for a range of autoimmune diseases. Sareum is also
developing SDC1802, a TYK2/JAK1 inhibitor with a potential application for
cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEKLFLLLLFFBX